贝伐珠单抗肾脏损害作用及机制

doi:10.3760/cma.j.issn.1673-422X.2014.08.014

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (8): 602-605.doi: 10.3760/cma.j.issn.1673-422X.2014.08.014

贝伐珠单抗肾脏损害作用及机制

何艺,徐群红,陈雪琴,潘月龙,王鸣

310006南京医科大学附属杭州医院（杭州市第一人民医院）肾内科(何艺、徐群红、王鸣)，肿瘤内科（陈雪琴、潘月龙）

收稿日期:2014-02-25 修回日期:2014-03-28 出版日期:2014-08-15 发布日期:2014-08-14
通讯作者: 徐群红，E-mail：helloxqh@sina.com E-mail:徐群红，E-mail：helloxqh@sina.com
基金资助:
杭州市卫生科技计划（2011Z002）；吴阶平医学基金会临床科研专项资助基金(320.6750.12364)

Effects and mechanisms of bevacizumab-induced renal impairment

He Yi, Xu Qunhong, Chen Xueqin, Pan Yuelong, Wang Ming

Department of Nephrology, Hangzhou Hospital Affiliated to Nanjing Medical University (Hangzhou First People′s Hospital), Hangzhou 310006, China

Received:2014-02-25 Revised:2014-03-28 Online:2014-08-15 Published:2014-08-14
Contact: Xu Qunhong E-mail:徐群红，E-mail：helloxqh@sina.com

摘要/Abstract

摘要： 贝伐珠单抗在肿瘤靶向治疗中已广泛应用，其最常见不良反应为肾脏损害，表现为蛋白尿，主要机制可能有干扰足细胞内皮血管内皮生长因子（VEGF）轴信号、继发性高血压致肾小球内压增加、内皮受损引起亚急性肾小球血栓性微血管病等。肾脏病理表现以血栓性微血管病为主，其他少见类型包括肾小球病变、肾间质病变、良性肾小球动脉硬化等。故贝伐珠单抗使用期间应密切监测尿蛋白和肾功能变化，及时治疗、减少药物剂量甚至停药，保护患者肾功能。

关键词: 贝伐珠单抗, 肾脏损害, 蛋白尿, 肾脏病理

Abstract: Bevacizumab has been widely used in tumor targeting therapy, while the most common adverse reaction is renal impairment, manifested as proteinuria. The main mechanisms may include interfering podocytesendothelial vascular endothelial growth factor(VEGF) axis signals, increasing glomerular pressure caused by secondary hypertension, subacute renal thrombotic microangiopathy caused by endothelial damage and so on. Thrombotic microangiopathy is the main renal pathological type, and other rare types include glomerular lesions, renal interstitial disease, and benign renal arteriolar nephrosclerosis. Therefore, urine protein excretion and renal function should be closely monitored during bevacizumab treatment period for timely treatment, dose reduction or even withdrawal if necessary to ensure renal function.

Key words: Bevacizumab, Renal impairment, Proteinuria, Renal pathology

何艺,徐群红,陈雪琴,潘月龙,王鸣. 贝伐珠单抗肾脏损害作用及机制[J]. 国际肿瘤学杂志, 2014, 41(8): 602-605.

He Yi, Xu Qunhong, Chen Xueqin, Pan Yuelong, Wang Ming. Effects and mechanisms of bevacizumab-induced renal impairment[J]. Journal of International Oncology, 2014, 41(8): 602-605.

参考文献

［1］ Vaziri SA, Kim J, Ganapathi MK, et al. Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors［J］. Curr Oncol Rep, 2010, 12(2): 102-108. ［2］ Deng T, Zhang L, Liu XJ, et al. Bevacizumab plus irinotecan, 5fluorouracil, and leucovorin (FOLFIRI) as the secondline therapy for patients with metastatic colorectal cancer, a multicenter study［J］. Med Oncol, 2013, 30(4):752. ［3］吴玉立, 吕超, 郑铎, 等. 贝伐珠单抗联合化疗治疗转移性结直肠癌的研究进展［J］. 国际肿瘤学杂志, 2013, 40(7): 503-506. ［4］ Raez LE, Santos ES, Webb RT, et al. A multicenter phase Ⅱ study of docetaxel, oxaliplatin， and bevacizumab in firstline therapy for unresectable locally advanced or metastatic nonsquamous cell histology nonsmallcell lung cancer (NSCLC)［J］. Cancer Chemother Pharmacol, 2013, 72(5): 1103-1110. ［5］ Melichar B, Bracarda S, Matveev V, et al. A multinational phase Ⅱ trial of bevacizumab with lowdose interferonα2a as firstline treatment of metastatic renal cell carcinoma: BEVLiN［J］. Ann Oncol, 2013, 24(9): 2396-2402. ［6］ Arakawa Y, Mizowaki T, Murata D, et al. Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma［J］. Neurol Med Chir (Tokyo), 2013, 53(11): 779-785. ［7］戴黎明, 李志强. 贝伐单抗对胶质瘤侵袭性的影响及其机制［J］. 国际肿瘤学杂志, 2012, 39(4): 259-261. ［8］ Reck M, von Pawel J, Zatloukal P, et al. Phase Ⅲ trial of cisplatin plus gemcitabine with either placebo or bevacizumab as firstline therapy for nonsquamous nonsmallcell lung cancer: AVAil［J］. J Clin Oncol, 2009, 27(8): 1227-1234. ［9］ Crinò L, Dansin E, Garrido P, et al. Safety and efficacy of firstline bevacizumabbased therapy in advanced nonsquamous nonsmallcell lung cancer (SaiL, MO19390): a phase 4 study［J］. Lancet Oncol, 2010, 11(8): 733-740. ［10］ Tesaˇrová P, Tesaˇr V. Proteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathwayincidence, mechanisms and management［J］. Folia Biol (Praha), 2013, 59(1): 15-25. ［11］ Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibitioninduced proteinuria: mechanisms, significance and management［J］. Eur J Cancer, 2010, 46(2): 439-448. ［12］ Teramachi H, Shiga H, Komada N, et al. Risk factors contributing to urinary protein expression resulting from bevacizumab combination chemotherapy［J］. Pharmazie, 2013, 68(3): 217-220. ［13］ Mourad JJ, des Guetz G, Debbabi H, et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation［J］. Ann Oncol, 2008, 19(5): 927-934. ［14］ Hayman SR, Leung N, Grande JP, et al. VEGF inhibition, hypertension, and renal toxicity［J］. Curr Oncol Rep, 2012, 14(4): 285-294. ［15］ Advani A, Connelly KA, Advani SL, et al. Role of the eNOSNO system in regulating the antiproteinuric effects of VEGF receptor 2 inhibition in diabetes［J］. Biomed Res Int, 2013, 2013: 201475. ［16］ Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy［J］. N Engl J Med, 2008, 358(11): 1129-1136. ［17］ Zhao J, Li H, Zhang L, et al. Clinical and pathological analyses of bevacizumabinduced renal impairment in four patients［J］. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2012, 34(2): 153-158. ［18］ Vigneau C, Lorcy N, DolleyHitze T, et al. All antivascular endothelial growth factor drugs can induce 'preeclampsialike syndrome′: a RARe study［J］. Nephrol Dial Transplant, 2014, 29(2): 325-332. ［19］ Izzedine H, Mangier M, Ory V, et al. Expression patterns of RelA and cmip are associated with different glomerular diseases following antiVEGF therapy［J］. Kidney Int, 2014, 85(2): 457-470. ［20］ Yahata M, Nakaya I, Sakuma T, et al. Immunoglobulin A nephropathy with massive paramesangial deposits caused by antivascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature［J］. BMC Res Notes, 2013, 6(1): 450. ［21］张静, 周文. 顺铂肾毒性相关机制及其防护研究现状［J］. 中国药学杂志, 2012, 47(22): 1785-1789. ［22］ Vrdoljak E, Boban M, Omrcen T, et al. Combination of capecitabine and mitomycin C as firstline treatment in patients with metastatic breast cancer［J］. Neoplasma, 2011, 58(2): 172-178. ［23］ Lomax AJ, Hill PA, Ashley DM. Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme［J］. J Oncol Pharm Pract, 2013, 19(4):365-368.

[1]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[2]	林榕生, 吴楚海, 郭颖梅, 王涛, 陈荣斌, 刘少琴, 甘兵. 特瑞普利单抗联合贝伐珠单抗二线以上治疗MSI-H型转移性结直肠癌的疗效及安全性[J]. 国际肿瘤学杂志, 2022, 49(2): 100-105.
[3]	李佳, 马晓捷, 王宇翔. 射频消融后辅助mFOLFOX6联合贝伐珠单抗方案在结直肠癌肝转移瘤中的疗效和安全性评价[J]. 国际肿瘤学杂志, 2021, 48(12): 729-734.
[4]	郑静, 姚胜, 沈文洁, 孙志佳, 赵辉, 付艳, 高珂, 杜楠. 腹腔灌注贝伐珠单抗联合白蛋白紫杉醇和卡铂治疗卵巢癌所致癌性腹腔粘连的临床探讨[J]. 国际肿瘤学杂志, 2021, 48(11): 660-665.
[5]	权瑞泉, 张丽, 匡黎, 李洪波, 肖梅仙. 奥拉帕尼联合贝伐珠单抗治疗复发性铂类敏感卵巢癌患者的疗效及对血清HE4、CA125、CTC水平的影响[J]. 国际肿瘤学杂志, 2020, 47(10): 606-610.
[6]	刘梦实，杨海燕，李红梅. 贝伐珠单抗治疗非小细胞肺癌脑转移[J]. 国际肿瘤学杂志, 2017, 44(11): 864-865.
[7]	于兰, 张小涛, 刘丽, 韩晓娜. 贝伐珠单抗在恶性脑水肿治疗中的应用[J]. 国际肿瘤学杂志, 2017, 44(1): 41-44.
[8]	黄少江. 白蛋白结合型紫杉醇联合贝伐珠单抗二线治疗晚期胰腺癌的临床观察[J]. 国际肿瘤学杂志, 2014, 41(8): 620-623.
[9]	潘雪峰, 邢红雨, 郑国宝. 贝伐珠单抗治疗脑胶质瘤及放射性脑坏死[J]. 国际肿瘤学杂志, 2014, 41(1): 27-30.
[10]	吴玉立, 吕超, 郑铎, 吴硕东. 贝伐珠单抗联合FOLFOX方案治疗转移性结直肠癌的研究进展[J]. 国际肿瘤学杂志, 2013, 40(7): 503-506.

贝伐珠单抗肾脏损害作用及机制

Effects and mechanisms of bevacizumab-induced renal impairment

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

本文评价